Rx drug tracking takes spotlight in House hearing

04/25/2013 | Reuters

U.S. lawmakers held a hearing Thursday to discuss a House draft bill that would require the tracking of medicines by lots, instead of tracing every drug unit as proposed in a Senate bill. Industry groups favor tracking by lots, saying that the technology needed to track individual saleable units is too costly, but the FDA favors the type of system outlined in the Senate bill. Strong national standards are essential to fight counterfeit medicines, according to Dr. Janet Woodcock, director of the FDA's Center for Drug Evaluation and Research. The FDA will need regulatory power to enforce adherence to the requirements, Woodcock added.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Actuary
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC